Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Paula del Cerro
Phase I-Ii Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation Using Fludarabine–melphalan Conditioning for Treatment of Mature T-Cell Lymphomas
Bone Marrow Transplantation
Transplantation
Hematology
Treosulfan Based Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation for Treatment of Patients With Non-Malignant Diseases: Preliminary Results of a Phase II Study
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Reduced Intensity Conditioning With Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation?
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With Fludarabine/Melphalan in Patients With Myelofibrosis
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
Haematologica
Hematology
Allogeneic Hematopoietic Stem Cell Transplantation
Archives of Internal Medicine
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Adults With Acute Myeloid Leukemia
Cancer Control
Medicine
Oncology
Hematology
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
